Latest filings (excl ownership)
EFFECT
Notice of effectiveness
29 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Other Events
21 Feb 24
S-3
Shelf registration
20 Feb 24
8-K
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
13 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Changes in Registrant's Certifying Accountant
26 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
18 Dec 23
8-K
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
11 Dec 23
8-K
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
9 Nov 23
10-Q
2024 Q1
Quarterly report
9 Nov 23
ARS
2023 FY
Annual report to shareholders
8 Nov 23
DEFA14A
Additional proxy soliciting materials
8 Nov 23
DEF 14A
Definitive proxy
8 Nov 23
DFAN14A
Additional proxy materials by non-management
1 Nov 23
DEFA14A
Additional proxy soliciting materials
1 Nov 23
8-K
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
1 Nov 23
10-K/A
2023 FY
Annual report (amended)
27 Oct 23
DEFA14A
Additional proxy soliciting materials
18 Oct 23
DEFC14A
Proxy in contested solicitation
17 Oct 23
PRER14A
Preliminary revised proxy
12 Oct 23
CORRESP
Correspondence with SEC
12 Oct 23
DFAN14A
Additional proxy materials by non-management
10 Oct 23
DEFC14A
Proxy in contested solicitation
10 Oct 23
8-A12B
Registration of securities on exchange
3 Oct 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
DEFA14A
Additional proxy soliciting materials
2 Oct 23
PREC14A
Preliminary proxy with contested solicitation
2 Oct 23
DFAN14A
Additional proxy materials by non-management
29 Sep 23
DEFA14A
Additional proxy soliciting materials
28 Sep 23
PRER14A
Preliminary revised proxy
28 Sep 23
CORRESP
Correspondence with SEC
28 Sep 23
DFAN14A
Additional proxy materials by non-management
26 Sep 23
8-K
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
26 Sep 23
10-K
2023 FY
Annual report
26 Sep 23
DEFC14A
Proxy in contested solicitation
26 Sep 23
UPLOAD
Letter from SEC
25 Sep 23
DFAN14A
Additional proxy materials by non-management
22 Sep 23
Latest ownership filings
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4/A
James P Flynn
12 Jan 24
4/A
Steven D Wood
12 Jan 24
4
Steven D Wood
20 Dec 23
4
James P Flynn
20 Dec 23
3
Steven D Wood
14 Nov 23
3
Taheer Datoo
6 Nov 23
3
James P Flynn
3 Nov 23
SC 13D/A
Anson Funds Management LP
1 Nov 23
4
Jacob Ma-Weaver
24 Oct 23
4
Bruce Ross Winson
24 Oct 23
SC 13D/A
Anson Funds Management LP
24 Oct 23
4
Jacob Ma-Weaver
13 Oct 23
4
Bruce Ross Winson
13 Oct 23
SC 13D/A
Anson Funds Management LP
13 Oct 23
4
Charles V. Baltic III
12 Oct 23
4
FREDERICK W DRISCOLL
12 Oct 23
4
Nicholas Glover
12 Oct 23
4
DANIEL P PHD GOLD
12 Oct 23
4
TAMAR D HOWSON
12 Oct 23
4
Thomas C Reynolds
12 Oct 23
4
SUJAY KANGO
12 Oct 23
4
RICHARD G GHALIE
12 Oct 23
SC 13D/A
Anson Funds Management LP
26 Sep 23
4
Bruce Ross Winson
25 Sep 23
4
Jacob Ma-Weaver
25 Sep 23
4
Bruce Ross Winson
22 Sep 23
4
Jacob Ma-Weaver
22 Sep 23
SC 13D/A
Anson Funds Management LP
22 Sep 23
SC 13D/A
Anson Funds Management LP
15 Sep 23
SC 13D/A
Anson Funds Management LP
8 Aug 23
3
Justin J. File
1 Aug 23
SC 13D/A
Anson Funds Management LP
17 Jul 23
4
David M Urso
6 Jun 23
3
Bruce Ross Winson
30 May 23
3
Jacob Ma-Weaver
30 May 23
SC 13D
Anson Funds Management LP
30 May 23
SC 13G
TANG CAPITAL PARTNERS LP
1 May 23
SC 13D/A
Growth Equity Opportunities V, LLC
9 Mar 23